Table 2. Rate ratio of target-vessel revascularization (TVR).

Authors	Comparator	Target-vessel revascularization
		1 year	2 years	≥ 3 years
[8] *	EES vs. BMS		0.31 [0.19–0.47]
	ZES vs. BMS		0.63 [0.42–0.96]
[9]	EES vs. BMS	0.28 [0.21–0.37]	0.39 [0.31–0.48]
	ZES vs. BMS	0.48 [0.36–0.66]	0.61 [0.48–0.77]
	Re-ZES vs. BMS	0.31 [0.17–0.57]	0.44 [0.27–0.68]
[10] *	EES vs. BMS		0.42 [0.26–0.62]
	ZES vs. BMS		0.96 [0.43–1.87]
	Re-ZES vs. BMS		0.26 [0.04–1.71]
[6]	EES vs. BMS	0.34 [0.22–0.52]
[11]	EES-Co-Cr vs. BMS	0.45 [0.29–0.66]	0.43 [0.28–0.62]
	PC-ZES vs. BMS	0.60 [0.34–1.05]	0.67 [0.40–1.16]
[12]	EES-Pt-Cr vs. BMS	0.30 [0.15–0.59]	0.34 [0.20–0.60]
	EES-Co-Cr vs. BMS	0.30 [0.23–0.39]	0.39 [0.32–0.48]
	Re-ZES vs. BMS	0.33 [0.19–0.58]	0.42 [0.27–0.66]
	PC-ZES vs. BMS	0.56 [0.40–0.77]	0.62 [0.49–0.80]
[13]	EES-Pt-Cr vs. BMS			0.34 [0.19–0.57]
	EES-Co-Cr vs. BMS			0.40 [0.32–0.49]
	Re-ZES vs. BMS			0.45 [0.29–0.68]
	PC-ZES vs. BMS			0.50 [0.41–0.62]
[14]	EES vs. BMS		0.29 [0.20–0.41]
[15] **	EES vs. BMS	0.55 [0.35–0.86]

Notes: BMS: Bare-metal stent, EES: Everolimus-eluting stent, ZES: Zotarolimus-eluting stent,

* Results at 6 months or more (up to 5 years)

** Results at 1 year or more; significant at 5% in bold.